What to expect in the Vericel Corp interview process

Based on publicly available sources, Vericel Corp. is a Cambridge, Massachusetts-headquartered biotechnology and pharmaceuticals company founded in 1989 that specializes in advanced cell therapies and specialty biologics for sports medicine and severe burn care. The company trades on the NASDAQ (VCEL) and maintains a global workforce of roughly 419 to 498 employees, alongside an office in Ann Arbor and a distributed international footprint spanning five countries.

While active hiring continues—with 39 active job postings noted in 2026, marking a slight 2.5% decline from the previous year—headcount has otherwise expanded steadily, growing by roughly 22.7% between 2023 and 2026. Total annual revenues sit around $276.3M.

Regarding compensation, benefits, and internal workplace dynamics, reported insights highlight a comprehensive yet uneven rewards experience. Strengths anchor on strong healthcare coverage, equity participation, and retirement support, though these are balanced by employee and candidate concerns regarding time-off depth, incentive reliability, and internal pay equity. On the business and stability front, Vericel benefits from unique FDA-approved market positions and sustained revenue and margin expansion, though it also faces concentration risks around its MACI product, competitive alternatives in knee restoration, and quarterly financial variability tied to seasonality and procurement timing. Workforce political leaning data among matched employees reflects a roughly balanced split of approximately 52.4% Democratic and 47.6% Republican.